Advances in bone cell biology over the past few decades have resulted in several new biochemical markers for the assessment of bone homeostasis. Since traditional diagnostic tools are inherently limited as they assess only the history and not the current status of disease, there arises a need for the development of new diagnostic tests that can detect the presence or the current status of disease, predict the future of disease progression & evaluate the response to therapy thereby improving the clinical management of the patients. CTx is a bone resorption marker produced during osteoclastic bone resorption and detected in urine or serum using ELISA. Serum CTx is a highly specific and sensitive marker of bone resorption that can rapidly indicate a patients response to bisphos phonate therapy.
